Short answer
Sanara MedTech Inc. (SMTI) filed its Q3 2025 10-Q quarterly report on Nov 12, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $26M (up 21.4% year over year) with net income of −$30M.
Q3 2025 key financials · XBRL
- Revenue
- $26M
- +21.4% YoY · +1.8% QoQ
- Net income
- −$30M
- −964.2% YoY · −1409.7% QoQ
- Operating margin
- 31.8%
- Gross margin
- 92.9%
- EPS (diluted)
- −$3.40
- −900.0% YoY · −1378.3% QoQ
Source: XBRL data from the Sanara MedTech Inc. (SMTI) Q3 2025 10-Q on SEC EDGAR. USD.
Sanara MedTech Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New financial risk: CRG Term Loan amendment allows up to two additional borrowings totaling $12.25 million by Dec 31, 2025, increasing debt capacity
- Most materially updated operational risk: Discontinuation of THP segment following persistent losses and failed investor interest, segment impairment of $31.2 million Q3 2025
- Most impactful legal/compliance risk: Licensing and Distribution Agreement with Biomimetic Innovations Limited includes milestone-based capital contributions totaling up to €7.0 million by 2026
- Near-term market risk: Sales growth (+22% Q3, +25% 9M YoY) driven by increased market penetration and geographic expansion in U.S. surgical soft tissue repair and bone fusion products
- Financial risk: Increased interest expense and fees due to higher borrowings under CRG Term Loan, other expense rose from $1.0 million to $2.1 million Q3 2025
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Sanara MedTech Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.